ArticleMolecular neurobiology2026
CCDC50 Alleviates Cerebral Ischemia-Reperfusion Injury via Enhancing Autophagy to Inhibit STING/IRF3-Mediated Microglial Polarization.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mild Hypothermia Alleviates Ischemia and Reperfusion Injury by Activating PINK1/Parkin Mitophagy.Neurochemical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ischemia-reperfusion injury (IRI) is a major reason for adverse prognosis in ischemic stroke, with multiple signaling pathways involved in this process. This study aims to explore the role of the novel autophagy receptor CCDC50 in cerebral IRI and its molecular mechanism. Cellular oxygen-glucose deprivation/reoxygenation model and middle cerebral artery occlusion (MCAO) animal model were adopted in this study. Quantitative real-time polymerase chain reaction, Western blot, immunofluorescence, and immunohistochemistry assays were applied to detect the expression and subcellular localization of key molecules including LL37, CCDC50, STING, IRF3, Rspondin3, and autophagy-related proteins. Co-immunoprecipitation was performed to explore protein-protein interactions. Enzyme-linked immunosorbent assay and flow cytometry were utilized to determine the levels of inflammatory cytokines and the M1/M2 polarization phenotypes of microglia. Additionally, 2,3,5-triphenyltetrazolium chloride staining was carried out to measure cerebral infarct volume. Results revealed that LL37 directly bound to CCDC50 and facilitated its ubiquitination and degradation. This process disrupted the interaction between CCDC50 and STING, thereby triggering the activation of the STING/IRF3 signaling pathway. Conversely, CCDC50 enhanced autophagy and restrained the STING/IRF3 pathway activation. It further drove microglial polarization toward the anti-inflammatory M2 phenotype, blocked pro-inflammatory M1 phenotype transition and inflammatory cytokine secretion, and ultimately alleviated neuronal damage. The above in vitro molecular mechanisms were also validated in the MCAO model. By enhancing autophagy, CCDC50 suppresses the STING/IRF3 pathway and facilitates M2 polarization of microglia, ultimately mitigating cerebral ischemia-reperfusion injury. In contrast, LL37 counteracts this protective effect by mediating CCDC50 degradation. This study identifies novel potential therapeutic targets for ischemic stroke.
Indexed as
Identifiers
42570179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.